Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortization of GoodwillAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maravai Lifesciences Holdings (MRVI) Cash from Financing Activities: 2020-2025

Historic Cash from Financing Activities for Maravai Lifesciences Holdings (MRVI) over the last 6 years, with Sep 2025 value amounting to -$8.2 million.

  • Maravai Lifesciences Holdings' Cash from Financing Activities fell 1119.65% to -$8.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$250.9 million, marking a year-over-year decrease of 26591.24%. This contributed to the annual value of -$235.7 million for FY2024, which is 285.84% down from last year.
  • Per Maravai Lifesciences Holdings' latest filing, its Cash from Financing Activities stood at -$8.2 million for Q3 2025, which was down 437.74% from -$1.5 million recorded in Q2 2025.
  • In the past 5 years, Maravai Lifesciences Holdings' Cash from Financing Activities ranged from a high of $809,000 in Q3 2024 and a low of -$236.2 million during Q4 2024.
  • Moreover, its 3-year median value for Cash from Financing Activities was -$1.5 million (2025), whereas its average is -$28.3 million.
  • In the last 5 years, Maravai Lifesciences Holdings' Cash from Financing Activities skyrocketed by 102.09% in 2023 and then crashed by 50,352.98% in 2024.
  • Maravai Lifesciences Holdings' Cash from Financing Activities (Quarterly) stood at -$49.6 million in 2021, then crashed by 33.37% to -$66.1 million in 2022, then soared by 100.71% to $470,000 in 2023, then tumbled by 50,352.98% to -$236.2 million in 2024, then slumped by 1,119.65% to -$8.2 million in 2025.
  • Its Cash from Financing Activities stands at -$8.2 million for Q3 2025, versus -$1.5 million for Q2 2025 and -$4.9 million for Q1 2025.